Evidence map›Paper›PMID 35127374›Full record

ReviewActa pharmaceutica Sinica. B2022

Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.

Shuwen Fu, Guanting Li, Wenli Zang, Xinyu Zhou, Kexin Shi, Yinglei Zhai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuwen FuSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Guanting LiDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Wenli ZangDepartment of Periodontology, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Disease, Shenyang 110016, China.
Xinyu ZhouBio-system Pharmacology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka 565-0871, Japan.
Kexin ShiDepartment of Biomedical Engineering, School of Medical Device, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yinglei ZhaiDepartment of Biomedical Engineering, School of Medical Device, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticulate drug delivery systems (Nano-DDSs) have emerged as possible solution to the obstacles of anticancer drug delivery. However, the clinical outcomes and translation are restricted by several drawbacks, such as low drug loading, premature drug leakage and carrier-related toxicity. Recently, pure drug nano-assemblies (PDNAs), fabricated by the self-assembly or co-assembly of pure drug molecules, have attracted considerable attention. Their facile and reproducible preparation technique helps to remove the bottleneck of nanomedicines including quality control, scale-up production and clinical translation. Acting as both carriers and cargos, the carrier-free PDNAs have an ultra-high or even 100% drug loading. In addition, combination therapies based on PDNAs could possibly address the most intractable problems in cancer treatment, such as tumor metastasis and drug resistance. In the present review, the latest development of PDNAs for cancer treatment is overviewed. First, PDNAs are classified according to the composition of drug molecules, and the assembly mechanisms are discussed. Furthermore, the co-delivery of PDNAs for combination therapies is summarized, with special focus on the improvement of therapeutic outcomes. Finally, future prospects and challenges of PDNAs for efficient cancer therapy are spotlighted.

Indexed as

ABC, accelerated blood clearanceACT, adoptive cell transferATO, atovaquoneATP, adenosine triphosphateBer, berberineBV, BiliverdinCancer treatmentCarrier-freeCe6, chlorine e6CI, combination indexCombination therapyCPT, camptothecinCTLs, cytotoxic T lymphocytesDBNP@CM, DBNP were cloaked with 4T1 cell membranesDBNP, DOX-Ber nano-assembliesDCs, dendritic cellsDOX, doxorubicinDPDNAs, dual pure drug nano-assembliesdsRNA, double-stranded RNAEGFR, epithelial growth factor receptorEPI, epirubicinEPR, enhanced permeability and retentionFRET, Forster Resonance Energy TransferGEF, gefitinibHCPT, hydroxycamptothecinHMGB1, high-mobility group box 1IC50, half maximal inhibitory concentrationICB, immunologic checkpoint blockadeICD, immunogenic cell deathICG, indocyanine greenITM, immunosuppressive tumor microenvironmentMDS, molecular dynamics simulationsMPDNAs, multiple pure drug nano-assembliesMRI, magnetic resonance imagingMTX, methotrexateNano-DDSs, nanoparticulate drug delivery systemsNanomedicineNanotechnologyNIR, near-infraredNPs, nanoparticlesNSCLC, non-small cell lung cancerPAI, photoacoustic imagingPD-1, PD receptor 1PD-L1, PD receptor 1 ligandPDNAs, pure drug nano-assembliesPDT, photodynamic therapyPoly I:C, polyriboinosinic:polyribocytidylic acidPPa, pheophorbide APTT, photothermal therapyPTX, paclitaxelPure drugQSNAP, quantitative structure-nanoparticle assembly predictionRBC, red blood cellRNA, ribonucleic acidROS, reactive oxygen speciesSelf-assemblySPDNAs, single pure drug nano-assembliesTA, tannic acidTEM, transmission electron microscopyTLR4, Toll-like receptor 4TME, tumor microenvironmentTNBC, triple negative breastTop I & II, topoisomerase I & IITTZ, trastuzumabUA, ursolic acidYSV, tripeptide tyroservatideZHO, Z-Histidine-Obzlα-PD-L1, anti-PD-L1 monoclonal antibody

Identifiers

PMID35127374
PMCPMC8799886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.